Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Genitourinary 2Sarcoma 1Head & Neck 1Classical hematology 1CNS 1

Conditions

Prostatic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × CK0238273 × Genitourinary × Clear all
NCT00354250 2013-06-05

Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00096499 2013-01-25

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡